OPKO and Pfizer receive regulatory clearance for global agreement
OPKO Health and Pfizer announced the closing of their worldwide agreement for the development and commercialization of hGH-CTP, a long-acting human growth hormone. The closing follows termination of the waiting period under the Hart-Scott Rodino Act. January 29, 2015